243 related articles for article (PubMed ID: 11937596)
1. 99mTc-sestamibi imaging in the assessment of toremifene as a modulator of multidrug resistance in patients with breast cancer.
Mubashar M; Harrington KJ; Chaudhary KS; Lalani el-N; Stamp GW; Sinnett D; Glass DM; Peters AM
J Nucl Med; 2002 Apr; 43(4):519-25. PubMed ID: 11937596
[TBL] [Abstract][Full Text] [Related]
2. Technetium-99m-sestamibi uptake by human benign and malignant breast tumor cells: correlation with mdr gene expression.
Cordobes MD; Starzec A; Delmon-Moingeon L; Blanchot C; Kouyoumdjian JC; Prévost G; Caglar M; Moretti JL
J Nucl Med; 1996 Feb; 37(2):286-9. PubMed ID: 8667063
[TBL] [Abstract][Full Text] [Related]
3. Differential effects of toremifene on doxorubicin, vinblastine and Tc-99m-sestamibi in P-glycoprotein-expressing breast and head and neck cancer cell lines.
Mubashar M; Harrington KJ; Chaudhary KS; Lalani el-N; Stamp GW; Peters AM
Acta Oncol; 2004; 43(5):443-52. PubMed ID: 15360048
[TBL] [Abstract][Full Text] [Related]
4. Technetium-99m-hexakis-2-methoxyisobutylisonitrile scintigraphy and multidrug resistance-related protein expression in human primary lung cancer.
Duan XY; Wang JS; Liu M; Guo YM
Ann Nucl Med; 2008 Jan; 22(1):49-55. PubMed ID: 18250987
[TBL] [Abstract][Full Text] [Related]
5. In vivo detection of multidrug-resistant (MDR1) phenotype by technetium-99m sestamibi scan in untreated breast cancer patients.
Vecchio SD; Ciarmiello A; Potena MI; Carriero MV; Mainolfi C; Botti G; Thomas R; Cerra M; D'Aiuto G; Tsuruo T; Salvatore M
Eur J Nucl Med; 1997 Feb; 24(2):150-9. PubMed ID: 9021112
[TBL] [Abstract][Full Text] [Related]
6. 99mTc-MIBI scintigraphy as a functional method for the evaluation of multidrug resistance in breast cancer patients.
Sergieva SB; Timcheva KV; Hadjiolov ND
J BUON; 2006; 11(1):61-8. PubMed ID: 17318954
[TBL] [Abstract][Full Text] [Related]
7. Modulation of the multidrug resistance P-glycoprotein: detection with technetium-99m-sestamibi in vivo.
Luker GD; Fracasso PM; Dobkin J; Piwnica-Worms D
J Nucl Med; 1997 Mar; 38(3):369-72. PubMed ID: 9074520
[TBL] [Abstract][Full Text] [Related]
8. Fractional retention of technetium-99m-sestamibi as an index of P-glycoprotein expression in untreated breast cancer patients.
Del Vecchio S; Ciarmiello A; Pace L; Potena MI; Carriero MV; Mainolfi C; Thomas R; D'Aiuto G; Tsuruo T; Salvatore M
J Nucl Med; 1997 Sep; 38(9):1348-51. PubMed ID: 9293785
[TBL] [Abstract][Full Text] [Related]
9. TC-99m MIBI SPECT imaging in patients with lung carcinoma: is it a functional probe of multidrug resistance genes?
Ak I; Gülbaş Z; Ocak S; Kaya E; Alataş F; Vardareli E; Metintaş M
J Comput Assist Tomogr; 2007; 31(5):795-9. PubMed ID: 17895794
[TBL] [Abstract][Full Text] [Related]
10. Expression of multidrug resistance protein and messenger RNA correlate with (99m)Tc-MIBI imaging in patients with lung cancer.
Zhou J; Higashi K; Ueda Y; Kodama Y; Guo D; Jisaki F; Sakurai A; Takegami T; Katsuda S; Yamamoto I
J Nucl Med; 2001 Oct; 42(10):1476-83. PubMed ID: 11585860
[TBL] [Abstract][Full Text] [Related]
11. Clinical validation of the influence of P-glycoprotein on technetium-99m-sestamibi uptake in malignant tumors.
Kostakoglu L; Elahi N; Kïratlï P; Ruacan S; Sayek I; Baltalï E; Sungur A; Hayran M; Bekdik CF
J Nucl Med; 1997 Jul; 38(7):1003-8. PubMed ID: 9225779
[TBL] [Abstract][Full Text] [Related]
12. Novel technetium (III)-Q complexes for functional imaging of multidrug resistance (MDR1) P-glycoprotein.
Crankshaw CL; Marmion M; Luker GD; Rao V; Dahlheimer J; Burleigh BD; Webb E; Deutsch KF; Piwnica-Worms D
J Nucl Med; 1998 Jan; 39(1):77-86. PubMed ID: 9443741
[TBL] [Abstract][Full Text] [Related]
13. Determination and prediction of P-glycoprotein and multidrug-resistance-related protein expression in breast cancer with double-phase technetium-99m sestamibi scintimammography. Visual and quantitative analyses.
Kim IJ; Bae YT; Kim SJ; Kim YK; Kim DS; Lee JS
Oncology; 2006; 70(6):403-10. PubMed ID: 17237619
[TBL] [Abstract][Full Text] [Related]
14. What can we expect from MDR breast cancer imaging with sestamibi?
Palmedo H
J Nucl Med; 2002 Apr; 43(4):526-30. PubMed ID: 11937597
[No Abstract] [Full Text] [Related]
15. Assessment of P-glycoprotein in patients with malignant bone and soft-tissue tumors using technetium-99m-MIBI scintigraphy.
Taki J; Sumiya H; Asada N; Ueda Y; Tsuchiya H; Tonami N
J Nucl Med; 1998 Jul; 39(7):1179-84. PubMed ID: 9669390
[TBL] [Abstract][Full Text] [Related]
16. 99mTc-MIBI imaging as a predictor of therapy response in osteosarcoma compared with multidrug resistance-associated protein and P-glycoprotein expression.
Burak Z; Moretti JL; Ersoy O; Sanli U; Kantar M; Tamgac F; Basdemir G
J Nucl Med; 2003 Sep; 44(9):1394-401. PubMed ID: 12960182
[TBL] [Abstract][Full Text] [Related]
17. The role of 99mTc-MIBI scintigraphy in the assessment of MDR1 overexpression in patients with musculoskeletal sarcomas: comparison with therapy response.
Burak Z; Ersoy O; Moretti JL; Erinç R; Ozcan Z; Dirlik A; Sabah D; Basdemir G
Eur J Nucl Med; 2001 Sep; 28(9):1341-50. PubMed ID: 11585293
[TBL] [Abstract][Full Text] [Related]
18. Expression of drug resistance protein related to Tc-99m MIBI breast imaging.
Sun SS; Hsieh JF; Tsai SC; Ho YJ; Kao CH
Anticancer Res; 2000; 20(3B):2021-5. PubMed ID: 10928145
[TBL] [Abstract][Full Text] [Related]
19. P-Glycoprotein and multidrug resistance-related protein expressions in relation to technetium-99m methoxyisobutylisonitrile scintimammography findings.
Kao CH; Tsai SC; Liu TJ; Ho YJ; Wang JJ; Ho ST; ChangLai SP
Cancer Res; 2001 Feb; 61(4):1412-4. PubMed ID: 11245443
[TBL] [Abstract][Full Text] [Related]
20. [The relationship between 99mTc-MIBI scintimammography of breast cancer and multidrug-resistant proteins].
Cui SD; Liu ZZ; Liu H; Li LF; Yang H; Li WL
Zhonghua Zhong Liu Za Zhi; 2005 Oct; 27(10):606-8. PubMed ID: 16438870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
